Alpha-synuclein and Parkinson disease

Neural Regeneration Research

Volumn 2, Issue 4, 2007, Pages 239-243

  Liu, Hui ^a   Wang, Xiaozhong ^a,b  

^a The 210th Hospital of PLA   (China)

^b DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Lewy's body; Parkinson's disease; synuclein

Indexed keywords

ALANINE; ALPHA SYNUCLEIN; DOPAMINE; PARKIN; PROLINE; SERINE; THREONINE;

ARTICLE; CELL DEATH; CENTRAL NERVOUS SYSTEM; CHROMOSOME 4Q; CYTOPLASM; DISEASE MODEL; DOPAMINERGIC SYSTEM; DRUG TARGETING; ENVIRONMENTAL FACTOR; GENE EXPRESSION; GENE MUTATION; GENE THERAPY; HEREDITY; HUMAN; INFORMATION PROCESSING; INHIBITION KINETICS; LEWY BODY; MEDICAL LITERATURE; MEDICAL RESEARCH; MEDLINE; MISSENSE MUTATION; NERVE CELL PLASTICITY; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRESYNAPTIC NERVE; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SECONDARY STRUCTURE; PROTEIN STRUCTURE; TRANSGENIC ANIMAL;

EID: 50849086820     PISSN: 16735374     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1673-5374(07)60053-X     Document Type: Article

References (43)

1. Nutt JG, Wooten GF. Clinical practice. Diagnosis and initial management of Parkinson's disease. N Engl J Med 2005;353(10):1021-7
2. Hardy J, Cai H, Cookson MR, et al. Genetics of Parkinson's disease and parkinsonism. Ann Neurol 2006;60(4): 389-98
3. Kruger R. Genes in familial parkinsonism and their role in sporadic Parkinson's disease. J Neurol 2004;251(S6):VI/2-6
4. Schapira AH. Etiology of Parkinson's disease. Neurology 2006;66(10 S4):S10-23
5. Liu S, Ninan I, Antonova I, et al. alpha-Synuclein produces a long-lasting increase in neurotransmitter release. EMBO J 2004;23(22):4506-16
6. Dachsel JC, Lincoln SJ, Gonzalez J, et al. The ups and downs of alpha-synuclein mRNA expression. Mov Disord 2007; 22(2):293-5
7. Lee JC, Langen R, Hummel PA, et al. Alpha-synuclein structures from fluorescence energy-transfer kinetics: implications for the role of the protein in Parkinsons disease. Proc Natl Acad Sci U S A 2004;101(47):16466-71
8. Chen T, Tang BS, Liao XP. Role of alpha-synuclein in the pathogenesis of Parkinson's disease. Chin J Neurology 2006; 39(6):415-8
9. Recchia A, Debetto P, Negro A, et al. Alpha-synuclein and Parkinson's disease. FASEB J 2004;18(6):617-26
10. Clough RL, Stefanis L. A novel pathway for transcriptional regulation of alpha-synuclein. FASEB J 2007;21(2): 596-607
11. Zhang W, Wang T, Pei Z, et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J 2005;19(6):533-42
12. Adamczyk A, Kazmierczak A, Strosznajder JB. Alpha-synuclein and its neurotoxic fragment inhibit dopamine uptake into rat striatal synaptosomes. Relationship to nitric oxide. Neurochem Int 2006;49(4):407-12
13. Kruger R, Kuhn W, Muller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998;18(2):106-8
14. Lee MK, Stirling W, Xu Y, et al. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53-Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci U S A 2002;99(13):8968-73
15. Periquet M, Fulga T, Myllykangas L, et al. Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. J Neurosci 2007;27(12): 3338-46
16. Neumann M, Kahle PJ, Giasson BJ, et al. Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J Clin Invest 2002;110(10):1429-39
17. Liani E, Eyal A, Avraham E, et al. Ubiquitylation of synphilin-1 and α-syn by SIAH and its presence in cellular inclusions and Lewy bodies imply a role in Parkinson's disease. Proc Natl Acad Sci U S A 2004;101(4):5500-5
18. Jenner P, Olanow CW. The pathogenesis of cell death in Parkinson's disease. Neurology 2006;66(10 S4):S24-36
19. Zhou W, Freed CR. Tyrosine-to-cysteine modification of human alpha-synuclein enhances protein aggregation and cellular toxicity. J Biol Chem 2004;279(11):10128-35
20. Mandal PK, Pettegrew JW, Masliah E, et al. Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease. Neurochem Res 2006;31(9):1153-62
21. Sharon R, Bar-Joseph I, Frosch MP, et al. The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 2003;37(4):583-95
22. Gispert S, Trenkwalder C, Mota-Vieira L, et al. Failure to find alpha-synuclein gene dosage changes in 190 patients with familial Parkinson disease. Arch Neurol 2005;62(1):96-8
23. Masliah E, Rockenstein E, Veinbergs I, et al. beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A 2001;98(21): 12245-50.
24. Martin LJ, Pan Y, Price AC, et al. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci 2006;26(1):41-50
25. Chen L, Feany MB. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci 2005;8(5):657-63
26. Giorgi FS, Bandettini di Poggio A, Battaglia G, et al. A short overview on the role of alpha-synuclein and proteasome in experimental models of Parkinson's disease. J Neural Transm Suppl 2006;(70):105-9
27. Eriksen JL, Wszolek Z, Petrucelli L. Molecular pathogenesis of Parkinson disease. Arch Neuron 2005;62(3):353-7
28. Fornai F, Schluter OM, Lenzi P, et al. Parkinson-like syndrome induced by continuous MPTP infiision: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc Natl Acad Sci U S A 2005;102(9):3413-8
29. Chen L, Feany MB. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci 2005;8(5):657-63
30. Hirai Y, Fujita SC, Iwatsubo T, et al. Phosphorytated alpha-synuclein in normal mouse brain. FEBS Lett 2004;572(1-3):227-32
31. Kahle PJ, Haass C. How does parkin ligate ubiquitin to Parkinson's disease? EMBO Rep 2004;5(7):681-5
32. Baptista MJ, Cookson MR, Miller DW. Parkin and alpha-synuclein: opponent actions in the pathogenesis of Parkinson's disease. Neuroscientist 2004;10(1):63-72
33. Nonaka T, Iwatsubo T, Hasegawa M. Ubiquitination of alpha-synuclein. Biochemistry 2005;44(1):361-8
34. Haywood AF, Staveley BE. Mutant alpha-synuclein-induced degeneration is reduced by parkin in a fly model of Parkinson's disease. Genome 2006;49(5):505-10
35. Kitao Y, Imai Y, Ozawa K, et al. Pael receptor induces death of dopaminergic neurons in the substantia nigra via endoplasmic reticulum stress and dopamine toxicity, which is enhanced under condition of parkin inactivation. Hum Mol Genet 2007;16(1):50-60
36. Yang Y, Nishimura I, Imai Y, et al. Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron 2003;37(6):911-24
37. Chandra S, Fornai F, Kwon HB, et al. Double-knockout mice for alpha and beta synucleins: effect on synaptic functions. Proc Natl Acad Sci U S A 2004;101(41):14966-71
38. Jao CC, Der-Sarkissian A, Chen J, et al. Structure of membrane-bound alpha-synuclein studied by site-directed spin labeling. Proc Natl Acad Sci U S A 2004;101(22):8331-36
39. Sato S, Chiba T, Sakata E, et al. 14-3-3eta is a novel regulator of parkin ubiquitin ligase. EMBO J 2006;25(1):211-21
40. Conway KA, Lee SJ, Rochet JC, et al. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A 2000;97(2):571-6
41. El-Agnaf OM, Paleologou KE, Greer B, et al. A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders. FASEB J 2004;18(11):1315-7
42. Fortin DL, Nemani VM, Voglmaier SM, et al. Neural activity controls the synaptic accumulation of alpha-synuclein. J Neurosci 2005;25(47):10913-21
43. Lo Bianco C, Schneider BL, Bauer M, et al. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. Proc Natl Acad Sci U S A 2004;101(50):17510-5